[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].
Identifieur interne : 001E16 ( Ncbi/Merge ); précédent : 001E15; suivant : 001E17[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].
Auteurs : F. Picard [France] ; E. Hirsch ; E. Salmon ; C. Marescaux ; M. CollardSource :
- Revue neurologique [ 0035-3787 ] ; 1996.
English descriptors
- KwdEn :
- Adult, Dopamine Agents (therapeutic use), Encephalitis (complications), Encephalitis, Viral (complications), Encephalitis, Viral (physiopathology), Humans, Levodopa (therapeutic use), Male, Movement Disorders (drug therapy), Movement Disorders (etiology), Movement Disorders (physiopathology), Parkinson Disease, Postencephalitic (drug therapy), Parkinson Disease, Postencephalitic (physiopathology), Time Factors.
- MESH :
- chemical , therapeutic use : Dopamine Agents, Levodopa.
- complications : Encephalitis, Encephalitis, Viral.
- drug therapy : Movement Disorders, Parkinson Disease, Postencephalitic.
- etiology : Movement Disorders.
- physiopathology : Encephalitis, Viral, Movement Disorders, Parkinson Disease, Postencephalitic.
- Adult, Humans, Male, Time Factors.
Abstract
In 1954, when he was five years old, a patient suffered from encephalitis with a prolonged lethargic state. Following this episode, he presented a severe parkinsonian syndrome which was associated, after a few years, with an axial dystonia and stereotyped involuntary movements of the upper limbs. These abnormal movements were particular by their coordinated appearance, their rhythmicity and their relative slowness. Treatment with L-dopa suppressed all akinetic, dystonic and dyskinetic symptoms. At age of 40 years, all the akinetic, dystonic and dyskinetic symptoms reappeared after drug withdrawal. Cerebral computed tomography, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography were normal. Fluorodopa positron emission tomography revealed a significant bilateral reduction of tracer accumulation in the posterior part of both putamen, similar to that observed in patients with idiopathic Parkinson's disease. In this patient, pharmacological tests revealed that effectiveness of L-dopa was abolished by administration of a D2 antagonist, and was fully reproduced by a D2 agonist. Clinical signs, pharmacological data and past-medical history strongly suggested a limited lesion of the zona compacta of substantia nigra induced by viral agression. This complex and progressive extrapyramidal syndrome had strong similarities with the lethargic encephalitis of Von Economo and its late symptoms. Other diseases associating akinesia and dyskinesia or dystonic phenomena, like dopa-sensitive dystonia and juvenile Parkinson's disease, are very unlikely. Thus, the persistance of sporadic forms of Von Economo's encephalitis could be discussed.
PubMed: 8763655
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001588
- to stream PubMed, to step Curation: 001547
- to stream PubMed, to step Checkpoint: 001547
Links to Exploration step
pubmed:8763655Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].</title>
<author><name sortKey="Picard, F" sort="Picard, F" uniqKey="Picard F" first="F" last="Picard">F. Picard</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hôpitaux Universitaires de Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hôpitaux Universitaires de Strasbourg</wicri:regionArea>
<wicri:noRegion>Hôpitaux Universitaires de Strasbourg</wicri:noRegion>
<wicri:noRegion>Hôpitaux Universitaires de Strasbourg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name>
</author>
<author><name sortKey="Salmon, E" sort="Salmon, E" uniqKey="Salmon E" first="E" last="Salmon">E. Salmon</name>
</author>
<author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name>
</author>
<author><name sortKey="Collard, M" sort="Collard, M" uniqKey="Collard M" first="M" last="Collard">M. Collard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1996">1996</date>
<idno type="RBID">pubmed:8763655</idno>
<idno type="pmid">8763655</idno>
<idno type="wicri:Area/PubMed/Corpus">001588</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001588</idno>
<idno type="wicri:Area/PubMed/Curation">001547</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001547</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001547</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001547</idno>
<idno type="wicri:Area/Ncbi/Merge">001E16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].</title>
<author><name sortKey="Picard, F" sort="Picard, F" uniqKey="Picard F" first="F" last="Picard">F. Picard</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hôpitaux Universitaires de Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hôpitaux Universitaires de Strasbourg</wicri:regionArea>
<wicri:noRegion>Hôpitaux Universitaires de Strasbourg</wicri:noRegion>
<wicri:noRegion>Hôpitaux Universitaires de Strasbourg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name>
</author>
<author><name sortKey="Salmon, E" sort="Salmon, E" uniqKey="Salmon E" first="E" last="Salmon">E. Salmon</name>
</author>
<author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name>
</author>
<author><name sortKey="Collard, M" sort="Collard, M" uniqKey="Collard M" first="M" last="Collard">M. Collard</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="1996" type="published">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Encephalitis (complications)</term>
<term>Encephalitis, Viral (complications)</term>
<term>Encephalitis, Viral (physiopathology)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (etiology)</term>
<term>Movement Disorders (physiopathology)</term>
<term>Parkinson Disease, Postencephalitic (drug therapy)</term>
<term>Parkinson Disease, Postencephalitic (physiopathology)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Encephalitis</term>
<term>Encephalitis, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease, Postencephalitic</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Encephalitis, Viral</term>
<term>Movement Disorders</term>
<term>Parkinson Disease, Postencephalitic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Humans</term>
<term>Male</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 1954, when he was five years old, a patient suffered from encephalitis with a prolonged lethargic state. Following this episode, he presented a severe parkinsonian syndrome which was associated, after a few years, with an axial dystonia and stereotyped involuntary movements of the upper limbs. These abnormal movements were particular by their coordinated appearance, their rhythmicity and their relative slowness. Treatment with L-dopa suppressed all akinetic, dystonic and dyskinetic symptoms. At age of 40 years, all the akinetic, dystonic and dyskinetic symptoms reappeared after drug withdrawal. Cerebral computed tomography, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography were normal. Fluorodopa positron emission tomography revealed a significant bilateral reduction of tracer accumulation in the posterior part of both putamen, similar to that observed in patients with idiopathic Parkinson's disease. In this patient, pharmacological tests revealed that effectiveness of L-dopa was abolished by administration of a D2 antagonist, and was fully reproduced by a D2 agonist. Clinical signs, pharmacological data and past-medical history strongly suggested a limited lesion of the zona compacta of substantia nigra induced by viral agression. This complex and progressive extrapyramidal syndrome had strong similarities with the lethargic encephalitis of Von Economo and its late symptoms. Other diseases associating akinesia and dyskinesia or dystonic phenomena, like dopa-sensitive dystonia and juvenile Parkinson's disease, are very unlikely. Thus, the persistance of sporadic forms of Von Economo's encephalitis could be discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8763655</PMID>
<DateCreated><Year>1996</Year>
<Month>10</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>1996</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Print"><Volume>152</Volume>
<Issue>4</Issue>
<PubDate><Year>1996</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].</ArticleTitle>
<Pagination><MedlinePgn>267-71</MedlinePgn>
</Pagination>
<Abstract><AbstractText>In 1954, when he was five years old, a patient suffered from encephalitis with a prolonged lethargic state. Following this episode, he presented a severe parkinsonian syndrome which was associated, after a few years, with an axial dystonia and stereotyped involuntary movements of the upper limbs. These abnormal movements were particular by their coordinated appearance, their rhythmicity and their relative slowness. Treatment with L-dopa suppressed all akinetic, dystonic and dyskinetic symptoms. At age of 40 years, all the akinetic, dystonic and dyskinetic symptoms reappeared after drug withdrawal. Cerebral computed tomography, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography were normal. Fluorodopa positron emission tomography revealed a significant bilateral reduction of tracer accumulation in the posterior part of both putamen, similar to that observed in patients with idiopathic Parkinson's disease. In this patient, pharmacological tests revealed that effectiveness of L-dopa was abolished by administration of a D2 antagonist, and was fully reproduced by a D2 agonist. Clinical signs, pharmacological data and past-medical history strongly suggested a limited lesion of the zona compacta of substantia nigra induced by viral agression. This complex and progressive extrapyramidal syndrome had strong similarities with the lethargic encephalitis of Von Economo and its late symptoms. Other diseases associating akinesia and dyskinesia or dystonic phenomena, like dopa-sensitive dystonia and juvenile Parkinson's disease, are very unlikely. Thus, the persistance of sporadic forms of Von Economo's encephalitis could be discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Picard</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hôpitaux Universitaires de Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hirsch</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Salmon</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marescaux</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Collard</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Syndrome Parkinsonien et mouvements involontaires stéréotypés post-encéphalitiques, sensibles à la L-dopa.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010301" MajorTopicYN="N">Parkinson Disease, Postencephalitic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year>
<Month>4</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1996</Year>
<Month>4</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1996</Year>
<Month>4</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8763655</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><noCountry><name sortKey="Collard, M" sort="Collard, M" uniqKey="Collard M" first="M" last="Collard">M. Collard</name>
<name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name>
<name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name>
<name sortKey="Salmon, E" sort="Salmon, E" uniqKey="Salmon E" first="E" last="Salmon">E. Salmon</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Picard, F" sort="Picard, F" uniqKey="Picard F" first="F" last="Picard">F. Picard</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001E16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:8763655 |texte= [Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8763655" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |